Dr Boyd is Founding President and Chief Scientific Officer of Translatum Medicus inc, and is an Ophthalmologist, specializing in diseases of the retina.  She is Director of the High Risk Dry AMD clinic and former Director of the Visual Electrophysiology Unit, at St Michael’s Hospital where she is a Clinician-Scientist, also overseeing the “Walter Retinal Research Laboratory”.  She is an Assistant Professor with the University of Toronto, Departments of Ophthalmology & Vision Sciences, and Laboratory Medicine & Pathobiology, and adjunct assistant professor of Biomedical Engineering, McMaster University.  She previously established the Ocular Phenotyping Facility at the Toronto Centre for Phenogenomics, Canada’s largest mutant mouse program, and is co-recipient of major awards in support of the Knock Out Mouse Program (KOMP) and for the development of novel ophthalmic biomaterials for drug delivery.

Dr Boyd was formerly Head of the Ocular Angiogenesis Research Program, global, for Novartis pharmaceuticals during the diligence, in-licensing and early development of Lucentis® with Genentech, USA.  There she oversaw the preclinical research and translational programs and was a member of joint Novartis-Genentech core committee.  She is also founding President and CEO of Tracery Ophthalmics inc, a clinical stage bioimaging and analytics company.

• 

  President and Chief Scientific Officer in Translatum Medicus Inc.

  AMD is the leading cause of irreversible blindness in the world and is growing globally.